| |  Online-Ressource |
|---|
| Verfasst von: | Nientiedt, Cathleen [VerfasserIn]  |
|---|
| | Heller, Martina [VerfasserIn] |
|---|
| | Endris, Volker [VerfasserIn] |
|---|
| | Volckmar, Anna-Lena [VerfasserIn] |
|---|
| | Zschäbitz, Stefanie [VerfasserIn] |
|---|
| | Tapia-Laliena, María Angeles [VerfasserIn] |
|---|
| | Jäger, Dirk [VerfasserIn] |
|---|
| | Schirmacher, Peter [VerfasserIn] |
|---|
| | Sültmann, Holger [VerfasserIn] |
|---|
| | Stenzinger, Albrecht [VerfasserIn] |
|---|
| | Hohenfellner, Markus [VerfasserIn] |
|---|
| | Grüllich, Carsten [VerfasserIn] |
|---|
| | Duensing, Stefan [VerfasserIn] |
|---|
| Titel: | Mutations in BRCA2 and taxane resistance in prostate cancer |
|---|
| Verf.angabe: | Cathleen Nientiedt, Martina Heller, Volker Endris, Anna-Lena Volckmar, Stefanie Zschäbitz, María A. Tapia-Laliena, Anette Duensing, Dirk Jäger, Peter Schirmacher, Holger Sültmann, Albrecht Stenzinger, Markus Hohenfellner, Carsten Grüllich & Stefan Duensing |
|---|
| E-Jahr: | 2017 |
|---|
| Jahr: | 4 July 2017 |
|---|
| Umfang: | 10 S. |
|---|
| Teil: | volume:7 |
|---|
| | year:2017 |
|---|
| | elocationid:4574 |
|---|
| | extent:10 |
|---|
| Fussnoten: | Gesehen am 09.10.2018 ; Im Titel ist "BRCA2" kursiv geschrieben |
|---|
| Titel Quelle: | Enthalten in: Scientific reports |
|---|
| Ort Quelle: | [London] : Macmillan Publishers Limited, part of Springer Nature, 2011 |
|---|
| Jahr Quelle: | 2017 |
|---|
| Band/Heft Quelle: | 7(2017), Artikel-ID 4574 |
|---|
| ISSN Quelle: | 2045-2322 |
|---|
| Abstract: | Mutations in BRCA1 or BRCA2 define a subset of prostate cancer patients. Herein, we address the question whether BRCA1/2 mutations have a predictive impact on chemotherapy with docetaxel, a widely used drug in patients with metastatic castration resistant prostate cancer (mCRPC). Fifty-three men treated with docetaxel for mCRPC were tested for somatic BRCA1/2 mutations of the primary tumor. In a subgroup of patients, BRCA1/2 protein expression was tested as a potential surrogate marker for BRCA1/2 inactivation. Eight of 53 patients (15.1%) harbored a deleterious BRCA2 mutation. No BRCA1 mutation was found. Patients with a BRCA2 mutation showed a response rate of 25% to docetaxel in comparison to 71.1% in men with wildtype BRCA2 (p = 0.019). While the time to develop castration resistance was similar in both subgroups, the overall survival was significantly shorter in patients harboring a BRCA2 mutation. No correlation between the BRCA1/2 protein expression and the response to docetaxel was found. While the presence of a BRCA2 mutation does not preclude a response to docetaxel, there is overall a significant correlation between BRCA2 inactivation and a poor response rate. Our results suggest that a close oncological monitoring of patients with BRCA2 mutations for taxane resistance is warranted. |
|---|
| DOI: | doi:10.1038/s41598-017-04897-x |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Kostenfrei: Volltext ; Verlag: http://dx.doi.org/10.1038/s41598-017-04897-x |
|---|
| | Kostenfrei: Volltext: https://www.nature.com/articles/s41598-017-04897-x |
|---|
| | DOI: https://doi.org/10.1038/s41598-017-04897-x |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 158169668X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Mutations in BRCA2 and taxane resistance in prostate cancer / Nientiedt, Cathleen [VerfasserIn]; 4 July 2017 (Online-Ressource)
